Eversept Partners’s AstraZeneca AZN Stock Holding History

Eversept Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-51,331	Closed	-$6.73M	–	60
2024 Q4	$6.73M	Buy	+51,331	New	+$7.19M	0.6%	34
2022 Q3	–	Sell	-510,165	Closed	-$67.4M	–	75
2022 Q2	$67.4M	Buy	510,165 +137,533	+37%	+$18M	4.79%	8
2022 Q1	$49.4M	Sell	372,632 -101,980	-21%	-$12.2M	3.8%	8
2021 Q4	$55.3M	Buy	474,612 +29,208	+7%	+$3.44M	3.53%	7
2021 Q3	$53.5M	Sell	445,404 -47,457	-10%	-$5.52M	3.7%	8
2021 Q2	$59M	Sell	492,861 -3,297	-0.7%	-$362K	3.94%	7
2021 Q1	$49.3M	Buy	496,158 +69,942	+16%	+$7.03M	3.71%	7
2020 Q4	$42.6M	Buy	426,216 +395,748	+1,299%	+$41.9M	5%	5
2020 Q3	$3.34M	Sell	30,468 -250,608	-89%	-$27.9M	0.74%	30
2020 Q2	$29.7M	Buy	281,076 +104,800	+59%	+$10.8M	4.08%	7
2020 Q1	$15.7M	Buy	176,276 +105,995	+151%	+$9.98M	3.91%	9
2019 Q4	$7.01M	Buy	+70,281	New	+$6.62M	1.24%	23

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Eversept Partners's AZN Position: Q1 2025 in Review

Eversept Partners sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 51,331 shares — an estimated $6.73M sold.

Eversept Partners first reported a position in AZN in Q4 2019 and held it in 12 quarters. The position peaked at $67.4M in Q2 2022. 1,250 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

Eversept Partners reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
Eversept Partners sold 51,331 AstraZeneca shares in Q1 2025, an estimated $6.73M.
Eversept Partners first reported a position in AstraZeneca in Q4 2019 and held it in 12 quarters.
Eversept Partners's AstraZeneca position peaked at $67.4M in Q2 2022.
1,250 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Eversept Partners's 13F filing for Q1 2025, filed 15 May 2025.